Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Abstract Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response has not been thoroughly elucidated. To better understand this, we studied a large cohort of melanoma patients treated with targeted therapy or immune checkpoint blockade (n = 60). Heterogeneity in therapeutic responses via radiologic assessment was observed in the majority of patients. Synchronous melanoma metastases were analyzed via deep genomic and immune profiling, and revealed substantial genomic and immune heterogeneity in all patients studied, with considerable diversity in T cell frequency, and few shared T cell clones (<8% on average) across the cohort. Variables related to treatment response were identified via these approaches and through novel radiomic assessment. These data yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This has also been observed in other cancer types such as melanoma”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reuben et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“20 This protocol was approved by the Institutional Review Board.”
Textural Features for Image Classification
Haralick, R. M., Shanmugam, K., & Dinstein, I. (1973) · IEEE Transactions on Systems, Man, and Cybernetics · doi:10.1109/tsmc.1973.4309314 · Cited by 22,886
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“2, 3 However, responses are heterogeneous and are not always durable.”
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 2×
“21, 22 Mutations in driver genes such as BRAF were also detected in 5/14 of patients (36%), as expected, and conserved across synchronous metastases, in-line with previous reports (Supplementary Fig.”
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 5×
“5, 6, 8, 9 However, the relationship between genomic and immune heterogeneity and link to tumor growth and response to therapy has not been extensively studied.”
InfluentialImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“35, 40 To better understand the relationship of the observed heterogeneous clinical responses with molecular and immune features within synchronous meta-static tumors, we performed an integrated analysis of genomic and immune features studied in our cohort as they relate to therapeutic response.”
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationClinical implications of intratumor heterogeneity: challenges and opportunities
Ramón y Cajal, S., Sesé, M., Capdevila, C., Aasen, T., De Mattos-Arruda, L., Diaz-Cano, S. J., Hernández-Losa, J., & Castellví, J. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01874-2 · Cited by 514
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458
“…of synchronous resected metastases with differential progression in patients withmelanoma has shown that intra-patient metastases present not only genetic heterogeneity but also immune-infiltration heterogeneity of immune cell types and T cell clonality between samples (Reuben et al., 2017).”
BackgroundPrimary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
“Similarly, a positive correlation was observed between a higher mutational load and increased CD8þ T-cell infiltration (39).”
Background
Metadata
- Authors
- Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., Jiang, H., Chen, P.-L., Beird, H. C., Garber, H. R., Roh, W., Wani, K., Chen, E., Haymaker, C., Forget, M.-A., Little, L. D., Gumbs, C., Thornton, R. L., Hudgens, C. W., Chen, W.-S., Austin-Breneman, J., Sloane, R. S., Nezi, L., Cogdill, A. P., Bernatchez, C., Roszik, J., Hwu, P., Woodman, S. E., Chin, L., Tawbi, H., Davies, M. A., Gershenwald, J. E., Amaria, R. N., Glitza, I. C., Diab, A., Patel, S. P., Hu, J., Lee, J. E., Grimm, E. A., Tetzlaff, M. T., Lazar, A. J., Wistuba, I. I., Clise-Dwyer, K., Carter, B. W., Zhang, J., Futreal, P. A., Sharma, P., Allison, J. P., Cooper, Z. A., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Reuben, Alexandre
- Spencer, Christine N.
- Prieto, Peter A.
- Gopalakrishnan, Vancheswaran
- Reddy, Sangeetha M.
- Miller, John P.
- Chen, Jiong
- Song, Xingzhi
- Jiang, Hong
- Chen, Pei-Ling
- Beird, Hannah C.
- Garber, Haven R.
- Roh, Whijae
- Wani, Khalida
- Chen, Eveline
- Haymaker, Cara
- Little, Latasha D.
- Gumbs, Curtis
- Hudgens, Courtney W.
- Chen, Wei-Shen
- Austin-Breneman, Jacob
- Sloane, Robert Szczepaniak
- Nezi, Luigi
- Cogdill, Alexandria P.
- Bernatchez, Chantale
- Roszik, Jason
- Hwu, Patrick
- Woodman, Scott E.
- Tawbi, Hussein
- Davies, Michael A.
- Gershenwald, Jeffrey E.
- Amaria, Rodabe N.
- Diab, Adi
- Patel, Sapna P.
- Hu, Jianhua
- Lee, Jeffrey E.
- Grimm, Elizabeth A.
- Tetzlaff, Michael T.
- Lazar, Alexander J.
- Wistuba, Ignacio I.
- Clise-Dwyer, Karen
- Carter, Brett W.
- Zhang, Jianhua
- Futreal, P. Andrew
- Sharma, Padmanee
- Allison, James P.
- Cooper, Zachary A.
- Wargo, Jennifer A.
- Venue
- npj Genomic Medicine
- Published
- 2017-04-07
- Volume
- 2
- Issue
- 1
- ISSN
- 2056-7944 (ISSN-L)
- PMC
- PMC5557036
- OpenAlex
- W2604777432
- Cited by
- 166
- References
- 48
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 10 · 2023: 19 · 2022: 14 · 2021: 49 · 2020: 17 · 2019: 16 · 2018: 19 · 2017: 6
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Genomic Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Prevention and Research Institute of Texas (P30 CA16672, R1204, R1205)
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (CA-16 672, CA093459)
- University of Texas MD Anderson Cancer Center (#CA16672, P30CA 16672, P50CA093459)
- National Cancer Institute (CA-16672, U54CA163125, T32CA163185, K08CA160692, T32CA009599, P30CA016672, P01CA163222, P50CA093459)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, genomic heterogeneity, immune heterogeneity, treatment response, targeted therapy, immune checkpoint blockade, synchronous metastases, T cell frequency, T cell clones, precision medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. https://app.cochat.ai/papers/10.1038/s41525-017-0013-8
- The paper
- Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., Jiang, H., Chen, P.-L., Beird, H. C., Garber, H. R., Roh, W., Wani, K., Chen, E., Haymaker, C., Forget, M.-A., . . . Wargo, J. A. (2017). Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. npj Genomic Medicine. https://doi.org/10.1038/s41525-017-0013-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.